[go: up one dir, main page]

TNSN02015A1 - Composes nouveaux antagonistes de ppar, et compositions les contenant - Google Patents

Composes nouveaux antagonistes de ppar, et compositions les contenant

Info

Publication number
TNSN02015A1
TNSN02015A1 TNTNSN02015A TNSN02015A TNSN02015A1 TN SN02015 A1 TNSN02015 A1 TN SN02015A1 TN TNSN02015 A TNTNSN02015 A TN TNSN02015A TN SN02015 A TNSN02015 A TN SN02015A TN SN02015 A1 TNSN02015 A1 TN SN02015A1
Authority
TN
Tunisia
Prior art keywords
compositions containing
antagonist compounds
ppar antagonist
novel ppar
compounds
Prior art date
Application number
TNTNSN02015A
Other languages
English (en)
Inventor
Myers Hayward Cheryl
Austen Perry David
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN02015A1 publication Critical patent/TNSN02015A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5004—Acyclic saturated phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L’INVENTION CONCERNE DES COMPOSES DE FORMULE (I): DANS LAQUELLE A, B, E, N, W, Z, R1, R2, R3, R5 ET R6 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS COMME ACTIVATEURS DE PPAR - alpha POUR LE TRAITEMENT DE DIVERSES MALADIES.
TNTNSN02015A 2001-02-15 2002-02-14 Composes nouveaux antagonistes de ppar, et compositions les contenant TNSN02015A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26905701P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
TNSN02015A1 true TNSN02015A1 (fr) 2005-12-23

Family

ID=23025619

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN02015A TNSN02015A1 (fr) 2001-02-15 2002-02-14 Composes nouveaux antagonistes de ppar, et compositions les contenant

Country Status (13)

Country Link
US (2) US20020169192A1 (fr)
EP (1) EP1372632A1 (fr)
JP (1) JP2004520397A (fr)
AP (1) AP2002002427A0 (fr)
BR (1) BR0207227A (fr)
CA (1) CA2438492A1 (fr)
GT (1) GT200200028A (fr)
MX (1) MXPA03007372A (fr)
PA (1) PA8539101A1 (fr)
PE (1) PE20021117A1 (fr)
SV (1) SV2003000887A (fr)
TN (1) TNSN02015A1 (fr)
WO (1) WO2002064130A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RU2356550C2 (ru) 2001-01-26 2009-05-27 Шеринг Корпорейшн Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CZ305202B6 (cs) 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1556373A1 (fr) * 2002-10-18 2005-07-27 Pfizer Products Inc. Ligands des recepteurs des cannabinoides et applications de ceux-ci
PL376326A1 (en) 2002-10-21 2005-12-27 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes and their use
PL376325A1 (en) * 2002-10-21 2005-12-27 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
ATE382043T1 (de) * 2003-02-14 2008-01-15 Lilly Co Eli Sulfonamid-derivate als ppar-modulatoren
US7173151B2 (en) 2003-02-27 2007-02-06 Sanofi-Aventisdeutschand Gmbh Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
DE10308356A1 (de) * 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
KR20060009846A (ko) * 2003-04-15 2006-02-01 화이자 인코포레이티드 Ｐｐａｒ 조절자로서의 알파 치환된 카복실산
WO2005027832A2 (fr) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Compositions contenant de l'acide edta et utilisations de ces dernieres
AR048931A1 (es) * 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2011145022A1 (fr) 2010-05-21 2011-11-24 Pfizer Inc. 2-phénylbenzoylamides
EP2680874A2 (fr) 2011-03-04 2014-01-08 Pfizer Inc Peptides de type edn3 et utilisations associées
AU2014247953A1 (en) * 2013-04-05 2015-11-12 Mitobridge, Inc. PPAR agonists
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
FR3109523B1 (fr) * 2020-04-23 2023-11-17 Univ Grenoble Alpes Nouveaux composés chaperons pharmacologiques de l’alpha-glucosidase acide humaine et leur utilisation thérapeutique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027023D0 (en) * 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
DE19504283A1 (de) * 1995-02-09 1996-08-14 Degussa Verfahren zur Herstellung von Cyanopyridinen und dafür geeignete Katalysatoren
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1998005331A2 (fr) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
AU737018B2 (en) * 1997-07-25 2001-08-09 Tsumura & Co. Pyridylacrylamide derivatives and nephritis remedies and TGF-beta inhibitors containing the same
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists

Also Published As

Publication number Publication date
SV2003000887A (es) 2003-03-18
WO2002064130A1 (fr) 2002-08-22
MXPA03007372A (es) 2003-12-04
BR0207227A (pt) 2004-02-10
PE20021117A1 (es) 2003-01-21
PA8539101A1 (es) 2002-09-30
EP1372632A1 (fr) 2004-01-02
US20020169192A1 (en) 2002-11-14
GT200200028A (es) 2002-10-01
AP2002002427A0 (en) 2002-03-31
US20050075377A1 (en) 2005-04-07
CA2438492A1 (fr) 2002-08-22
JP2004520397A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
TNSN01019A1 (fr) Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
TNSN02037A1 (fr) Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant
TNSN02008A1 (fr) Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02011A1 (fr) Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant
TNSN01047A1 (fr) Procede pour la preparation de derives de piperazine nouveaux
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01114A1 (fr) Derives d'imidazole nouveaux et compositions les contenant
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN01150A1 (fr) Pyrimidine-2,4,6- triones inhibitrices de metalloproteinases, et compositions les contenant.
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
TNSN01132A1 (fr) Derives de pyrazole nouveaux et compositions les contenant.
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN00169A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant
TNSN01149A1 (fr) Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant.
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques